ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1774

Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease

José Lisbona-Montañez1, Patricia Ruiz-Limon2, Arkaitz Mucientes3, Natalia Mena Vazquez4, Isabel Moreno-Indias3, SARA MANRIQUE5, Laura Cano-García6, Rocío Redondo-Rodríguez6, Francisco J tinahones3 and Antonio Fernandez-Nebro7, 1Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, 2IBIMA Plataforma BIONAND, Cordoba, Spain, 3IBIMA Plataforma BIONAND, Málaga, Spain, 4IBIMA, Málaga, Spain, 5Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 6Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, 7Hospital Regional Universitario de Málaga, Malaga, Spain

Meeting: ACR Convergence 2023

Keywords: Biomarkers, interstitial lung disease, microbiome, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Gut microbiota has been related to rheumatoid arthritis (RA), inflammation, and it’s severity. Interstitial lung disease (ILD) is the most frequent non-pleural pulmonary manifestation and causes high morbidity and mortality in RA patients. However, the association between gut microbiota and RA associated ILD (RA-ILD) is still unknown. In the same way, there are currently no useful biomarkers for the diagnosis and prognosis of RA-ILD. Therefore, the objective of the present study is to analyze gut microbiota and permeability in RA-ILD patients and evaluate it´s association with RA-ILD and pulmonary progression.

Methods: Nested case-cohort study of 2 prospective cohorts of patients with RA with and without ILD. The cohorts were matched for age, sex, and time of RA evolution. All cases systematically underwent high-resolution computed tomography (HRCT) and pulmonary function testing (PFT) on the diagnosis of ILD. ILD was defined according to lung biopsy or HRCT based on the standard criteria of the American Thoracic Society/European Respiratory Society. Pulmonary progression was defined as the worsening of the FVC > 10% or DLCO > 15%. Gut microbiota was measured by the 16S rRNA gene and the sequences were processed using the Quantitative Insights into Microbial Ecology (QIIME2). Serum lipopolysaccharide-binding protein (LBP) and lipopolysaccharide (LPS) were measured as markers of gut permeability. Demographic, clinical, laboratory, and treatment-related data were recorded. Disease activity was measured by Disease Activity Score-28 with Erythrocyte Sedimentation Rate (DAS28-ESR), and the function using the Health Assessment Questionnaire (HAQ). We performed a descriptive analysis and Cox regression analysis to identify factors associated with ILD.

Results: 35 RA-ILD and 35 RA without ILD patients were included. After a mean (SD) period of 66,1 (47,2) months, pulmonary progression criteria was observed in 13 patients (37.1%). Compared with controls, RA-ILD had greater values of DAS28-ESR (p=0.032) and higher HAQ scores (p=0.003). They also had higher levels of serum LPS (p = 0.007) and more abundance of Streptococcus genus (p = 0.087), as well as a lower abundance of Slackia (p = 0.022) and Paraprevotella genera (p = 0.082). RA-ILD patients with pulmonary progression had a higher abundance of Streptococcus genus (p = 0.090) and a lower abundance of Slackia genus. In Cox regression analysis, the moderate-high activity of DAS28-ESR (HR [IC 95%], 3.53 [1.20-6.98]; p=0.017), LPS (HR [IC 95%], 1.12 [1.02-1.23]; p=0.018) and the Slackia genus (HR [IC 95%], 0.98 [0.97-0.99]; p=0.010) were associated with RA-ILD.

Conclusion: RA-ILD patients showed increased gut permeability and also displayed a different pattern of gut microbiota associated with ILD diagnosis and prognosis. These findings may enable the discovery of potential RA-ILD biomarkers.

Supporting image 1

Clinical and demographic characteristics:
Abbreviations. ACPA: anticitrullinated peptide antibody; DAS28: Disease activity score; DLCO: diffusing capacity of the lung for carbon monoxide; DMARDs: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; HAQ: Health Assessment Questionnaire; HCRT: high-resolution computed tomography; NSIP: nonspecific interstitial pneumonia; RF: rheumatoid factor; SD: standard deviation; UIP: usual interstitial pneumonia.

Supporting image 2

Microbiota analysis:
Alpha diversity (above) and Beta diversity (bottom). To compare the populations of both groups, the Jaccard similarity index was used and significant differences (p=0.017) were observed between both groups. Blue dots: RA without ILD; Pink dots: RA-ILD.

Supporting image 3

Gut microbiota profile:
Graphs represent the families and genera with statistically significant differences. At the family level, Paraprevotellaceae (p=0.007) was significantly decreased, while Streptococcaceae (p=0.050) was significantly increased in RA-ILD patients compared to RA patients without ILD. At the genus level, Paraprevotella (p=0.007) and Slackia (p=0.041) were significantly decreased, while Streptococcus (p=0.050) was significantly increased in RA-ILD patients compared to RA patients without ILD.


Disclosures: J. Lisbona-Montañez: None; P. Ruiz-Limon: None; A. Mucientes: None; N. Mena Vazquez: None; I. Moreno-Indias: None; S. MANRIQUE: None; L. Cano-García: None; R. Redondo-Rodríguez: None; F. tinahones: None; A. Fernandez-Nebro: None.

To cite this abstract in AMA style:

Lisbona-Montañez J, Ruiz-Limon P, Mucientes A, Mena Vazquez N, Moreno-Indias I, MANRIQUE S, Cano-García L, Redondo-Rodríguez R, tinahones F, Fernandez-Nebro A. Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/gut-microbiota-and-permeability-biomarkers-for-diagnosis-and-prognosis-in-rheumatoid-arthritis-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gut-microbiota-and-permeability-biomarkers-for-diagnosis-and-prognosis-in-rheumatoid-arthritis-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology